New Research Partnership will Leverage BERG’s Interrogative Biology® Platform to Identify Novel Biomarker and Targets for Diagnosis and Treatment of Alzheimer’s Disease

BERG’s Interrogative Biology® Platform will Evaluate Clinically Annotated Biospecimens to Discover Diagnostic Biomarkers and Treatments for Neurological Diseases BOSTON — BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, Massachusetts General Hospital (MGH), and Brigham and Women’s Hospital (BWH) today announced a research partnership to enhance the understanding of…